The incidence and characterization of weight gain associated with MEK inhibitors in pediatric patients.
MEK inhibitor
selumetinib
side effect
trametinib
weight gain
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
revised:
12
11
2022
received:
29
06
2022
accepted:
04
12
2022
pubmed:
31
1
2023
medline:
25
2
2023
entrez:
30
1
2023
Statut:
ppublish
Résumé
Mitogen-activated protein kinase enzyme (MEK) inhibitors are used in the treatment of pediatric patients with neurofibromatosis, low grade glioma, and astrocytoma, and may demonstrate a unique side effect profile in this population. Inhibition of MEK has been shown to decrease interleukin (IL)-6 production, a proinflammatory cytokine. The inhibition of IL-6 and other proinflammatory cytokines is thought to decrease muscle wasting and may contribute to weight gain. However, there is limited information on the association of MEK inhibition and weight gain in children and adolescents. This study aimed to characterize and define the incidence of significant weight gain associated with MEK inhibitors in pediatric patients. This was a retrospective chart review conducted at a tertiary pediatric hospital. Children 1-18.99 years old were included if they started a MEK inhibitor from July 1, 2013-October 31, 2021, and continued therapy for at least 6 months. Significant weight gain was defined as ≥5% increase in patient's weight-for-age percentile. Sixty-seven patients were included in the analysis. Sixty-two received trametinib and 5 received selumetinib. An increase in weight-for-age percentile ≥5% was seen in 60% of patients receiving selumetinib and 56% on trametinib. The Dunnett's multiple comparisons test revealed a difference in weight-for-age percentile from baseline to end of data collection (p = .0173). Patients who were obese at baseline were more likely to lose weight during treatment, while underweight patients increased in weight-for-age percentiles. Weight gain may be a notable side effect associated with the use of MEK inhibitors in pediatric patients.
Sections du résumé
BACKGROUND
Mitogen-activated protein kinase enzyme (MEK) inhibitors are used in the treatment of pediatric patients with neurofibromatosis, low grade glioma, and astrocytoma, and may demonstrate a unique side effect profile in this population. Inhibition of MEK has been shown to decrease interleukin (IL)-6 production, a proinflammatory cytokine. The inhibition of IL-6 and other proinflammatory cytokines is thought to decrease muscle wasting and may contribute to weight gain. However, there is limited information on the association of MEK inhibition and weight gain in children and adolescents. This study aimed to characterize and define the incidence of significant weight gain associated with MEK inhibitors in pediatric patients.
METHODS
This was a retrospective chart review conducted at a tertiary pediatric hospital. Children 1-18.99 years old were included if they started a MEK inhibitor from July 1, 2013-October 31, 2021, and continued therapy for at least 6 months. Significant weight gain was defined as ≥5% increase in patient's weight-for-age percentile.
RESULTS
Sixty-seven patients were included in the analysis. Sixty-two received trametinib and 5 received selumetinib. An increase in weight-for-age percentile ≥5% was seen in 60% of patients receiving selumetinib and 56% on trametinib. The Dunnett's multiple comparisons test revealed a difference in weight-for-age percentile from baseline to end of data collection (p = .0173). Patients who were obese at baseline were more likely to lose weight during treatment, while underweight patients increased in weight-for-age percentiles.
CONCLUSIONS
Weight gain may be a notable side effect associated with the use of MEK inhibitors in pediatric patients.
Substances chimiques
Cytokines
0
Mitogen-Activated Protein Kinase Kinases
EC 2.7.12.2
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30182Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Wu PK, Park JI. MEK1/2 inhibitors: molecular activity and resistance mechanisms. Semin Oncol. 2015;42(6):849-862.
Lexi Drugs. LexiComp. Wolters Kluwer. Hudson, OH. Available at: http://www.online.lexi.com
Talbert EE, Yang J, Mace TA, et al. Dual inhibition of MEK and PI3K/Akt rescues cancer cachexia through both tumor extrinsic and intrinsic activities. Mol Cancer Ther. 2017;16(2):344-56
Dumont FJ, Staruch MJ, Fischer P, DaSilva C, Camacho R. Inhibition of T cell activation by pharmacologic disruption of MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production. J Immunol. 1998;160:2579-2589.
Baracos VE. Mitogen-activated protein kinases inhibitors: potential therapeutic agents for cancer cachexia. Mol Cancer Ther. 2017;16(2):263-264.
Quan-Jun Y, Yan H, Yong-Long H, et al. Selumetinib attenuate skeletal muscle wasting in murine cachexia model through ERK inhibition and AKT activation. Mol Cancer Ther. 2016;16:332-41.
Prado CM, Bekaii-Saab T, Doyle LA, et al. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br J Cancer. 2012;106(10):1583-1586. doi:10.1038/bjc.2012.144
Yeh S, Wu S, Levine DM, et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. J Gerontol. 2001:56(1):M48-M54.
Bekaii-Saab T, Phelps MA, Li X, et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011;29(17):2357-2363.
Finn, RS, Ahn, DH, Javle, MM, et al. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer. Investigational New Drugs. 2018;36(6):1037-1043.
Banerjee A, Jakacki RI, Onar-Thomas A, et al. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol. 2017;19(8):1135-1144.
Fangusaro J, Onar-Thomas A, Poussiant TY, et al. Selumetinib in children with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory or progressive low-grade glioma: a multi-center phase II trial. Lancet Oncol. 2019;20(7):1011-1022.
Klesse LJ, Jordan JT, Radtke HB, et al. The use of MEK inhibitors in neurofibromatosis type 1-associated tumors and management of toxicities. Oncologist. 2020;25(7):e1109-e1116.
Beer SS, Juarez MD, Vega MW, Canada NL. Pediatric malnutrition: putting the new definition and standards into practice. ASPEN: Nutrition in Clinical Practice. 2015;30(5):609-624.
Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. National Cancer Institute. Updated November 27, 2017.
Rankin AW, Annam A, Chatfield K, et al. Trametinib for refractory chylous effusions in children with Noonan syndrome. Blood: 63rdASH Annual Meeting Abstracts. 2021; 3140-3142.
Prado CM, Bekaii-Saab T, Doyle LA, et al. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br J Cancer. 2012;106(10):1583-1586.
Griggs JJ, Bohlke K, Balaban E, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO Guideline Update. J Clin Oncol. 2021;39(18):2037-2048.